Everything below concerns peptide hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Styrene-butane co-polymers do not break at this point, but begin to flow, solidify to tensile strength and only break at much higher elongation. With a high proportion of polybutadiene, the effect of the two phases is reversed. Styrene-butadiene rubber behaves like an elastomer but can be processed like a thermoplastic.
There is evidence that suggests that wind turbines might create sufficient barotrauma (pressure damage) to kill bats. Bats have typical mammalian lungs, which are thought to be more sensitive to sudden air pressure changes than the lungs of birds, making them more liable to fatal rupture. Bats may approach turbines to roost on them, increasing the death rate. Ultrasonic signals may help to deter bats from approaching wind farms, thus reducing deaths. The diagnosis and contribution of barotrauma to bat deaths near wind turbine blades have been disputed by other research comparing dead bats found near wind turbines with bats killed by impact with buildings in areas with no turbines. The effects of climate change on bats are debated; a 2022 literature review concluded that, "Several biological and ecological traits of bats may make them sensitive to climate change, yet there is surprisingly little evidence on how these mammals respond to this anthropogenic environmental pressure." A 2025 study of European species found that bat populations may be shifting their ranges further north. Specifically, range suitability declined markedly in southern Europe while increasing at higher northern latitudes.
Vaginal anomalies are defects that result in an abnormal or absent vagina. The most common obstructive vaginal anomaly is an imperforate hymen, a condition in which the hymen obstructs menstrual flow or other vaginal secretions. Another vaginal anomaly is a transverse vaginal septum, which partially or completely blocks the vaginal canal. The precise cause of an obstruction must be determined before it is repaired, since corrective surgery differs depending on the cause. In some cases, such as isolated vaginal agenesis, the external genitalia may appear normal. Abnormal openings known as fistulas can cause urine or feces to enter the vagina, resulting in incontinence. The vagina is susceptible to fistula formation because of its proximity to the urinary and gastrointestinal tracts. Specific causes are manifold and include obstructed labor, hysterectomy, malignancy, radiation, episiotomy, and bowel disorders. A small number of vaginal fistulas are congenital. Various surgical methods are employed to repair fistulas. Untreated, fistulas can result in significant disability and have a profound impact on quality of life. Vaginal evisceration is a serious complication of a vaginal hysterectomy and occurs when the vaginal cuff ruptures, allowing the small intestine to protrude from the vagina. Cysts may also affect the vagina. Various types of vaginal cysts can develop on the surface of the vaginal epithelium or in deeper layers of the vagina and can grow to be as large as 7 cm. Often, they are an incidental finding during a routine pelvic examination.
=== Retracted isotopes === In 2003, scientists at the FLNR claimed to have discovered 249No, which would have been the lightest known isotope of nobelium. However, subsequent work showed that the 54 μs fission activity instead originated from an excited state of 250No. The discovery of this isotope was later reported in 2020; its decay properties differed from the 2003 claims.
Artificial intelligence (AI) is the capability of computational systems to perform tasks typically associated with human intelligence, such as learning, reasoning, problem-solving, perception, and decision-making. It is a field of research in engineering, mathematics, and computer science that develops and studies methods and software that enable machines to perceive their environment and use learning and intelligence to take actions that maximise their chances of achieving defined goals. High-profile applications of AI include advanced web search engines, chatbots, virtual assistants, autonomous vehicles, play and analysis in strategy games (e.g., chess and Go), and content generation (e.g., text, images, audio, and videos). The traditional goals of AI research include learning, reasoning, knowledge representation, planning, natural language processing, and perception, as well as support for robotics. To reach these goals, AI researchers use techniques including state space search and mathematical optimisation, formal logic, artificial neural networks, and methods based on statistics, operations research, and economics. AI also draws upon psychology, linguistics, philosophy, neuroscience, and other fields. Some companies, such as OpenAI, Google DeepMind, and Meta, aim to create artificial general intelligence (AGI)—AI that can complete nearly any cognitive task at least as well as a human. Artificial intelligence was founded as an academic discipline in 1956.
Sources: en.wikipedia.org
Chumming (American English from Powhatan) is the blue water fishing practice of throwing meat-based groundbait called "chum" into the water in order to lure various marine animals (usually large game fish) to a designated fishing ground, so the target animals are more easily caught by hooking or spearing. Chums typically consist of fresh chunks of fish meat with bone and blood, the scent of which attracts predatory fish, particularly sharks, billfishes, tunas and groupers. In the past, the chum contents have also been made from "offal", the otherwise rejected or unwanted parts of slaughtered animals such as internal organs.
Bach MK, Brashler JR, Morton DR Jr (1984). "Solubilization and characterization of the leukotriene C4 synthetase of rat basophil leukemia cells: a novel, particulate glutathione S-transferase". Arch. Biochem. Biophys. 230 (2): 455–65. doi:10.1016/0003-9861(84)90426-0. PMID 6324687. Shimizu T (1988). "Enzymes functional in the syntheses of leukotrienes and related compounds". Int. J. Biochem. 20 (7): 661–6. doi:10.1016/0020-711X(88)90160-7. PMID 2846379. Lam BK, Austen KF (2002). "Leukotriene C4 synthase: a pivotal enzyme in cellular biosynthesis of the cysteinyl leukotrienes". Prostaglandins. Other. Lipid. Mediat. 68–69: 511–20. doi:10.1016/S0090-6980(02)00052-7. PMID 12432940. Christmas P, Weber BM, McKee M, Brown D, Soberman RJ (2002). "Membrane localization and topology of leukotriene C4 synthase". J. Biol. Chem. 277 (32): 28902–8. doi:10.1074/jbc.M203074200. PMID 12023288.
=== Sahrawi Arab Democratic Republic === The Castillo Administration recognized the Sahrawi Arab Democratic Republic, a partially-recognized state claimed by Morocco. Although the recognition came without forewarning, officially it was due to Castillo's push for a foreign policy based on self-determination and non-intervention. The Congressional opposition has opposed the recognition of the SADR, claiming that it creates geopolitical instability and risks Peru's relations with the Middle East.
C-4 is very stable and insensitive to most physical shocks. C-4 cannot be detonated by a gunshot or by dropping it onto a hard surface. It does not explode when set on fire or exposed to microwaves. Detonation can be initiated only by a shockwave, such as when a detonator inserted into it is fired. When detonated, C-4 rapidly decomposes to release nitrogen, water and carbon oxides as well as other gases. The detonation proceeds at an explosive velocity of 8,092 m/s (26,550 ft/s). A major advantage of C-4 is that it can easily be molded into any desired shape to change the direction of the resulting explosion. C-4 has high cutting ability. For example, the complete severing of a 36-centimetre (14 in) deep I-beam takes between 680 and 910 g (1.50 and 2.01 lb) of C-4 when properly applied in thin sheets.
=== Pharmacodynamics === Dextromethorphan acts as an NMDA receptor antagonist, σ1 receptor agonist, and serotonin–norepinephrine reuptake inhibitor, among other actions, while bupropion acts as a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator. Bupropion is also a potent inhibitor of CYP2D6, and thereby inhibits the metabolism of dextromethorphan. Dextromethorphan/bupropion has less activity as an NMDA receptor antagonist than dextromethorphan alone. This is because bupropion is a potent CYP2D6 inhibitor and prevents the bioactivation of dextromethorphan into dextrorphan, a much more potent NMDA receptor antagonist and weaker serotonin reuptake inhibitor than dextromethorphan itself. The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown, although the preceding pharmacological actions are assumed to be involved.
Sources: en.wikipedia.org
=== Available forms === Suvorexant is available in the form of 5, 10, 15, and 20 mg oral film-coated tablets. It is provided as 10- and 30-tablet blister packs as well as 3-tablet starter packs. The availability of these different packs varies by country.
In the 1980s, Mister Donut was the largest competitor to Dunkin'. On March 31, 1987, Elie G. Saheb and his business associates acquired the trademark rights for Mister Donut in the United Kingdom and afterwards opened a Mister Donut pilot store and bakery in Fulham, London. On May 2, 1988, the Mister Donut franchise sold the trademark rights for the European market at large. By the 1980s, Mister Donut had over 550 stores in the United States and Canada. In 1989, the British corporate giant Allied-Lyons plc acquired Dunkin' Donuts from Rosenberg for a reported £196 million. After becoming a subsidiary of Allied-Lyons, Dunkin' Donuts immediately acquired Mister Donut from International Multifoods. Mister Donut stores were offered the option to convert to Dunkin', while all remaining Mister Donut franchises in the rest of the world started being operated on their own such as in Japan and El Salvador. Mister Donut sold its Middle East trademarks on October 14, 1995. In July 2005, Allied-Lyons was acquired by Pernod Ricard SA. On December 12, 2005, Pernod Ricard announced that it had agreed to sell Dunkin' Brands, which owned Dunkin' and Mister Donut, to a consortium of three US private equity firms (Thomas H. Lee Partners, the Carlyle Group and Bain Capital LLP) for US$2.43 billion. The closing of the sale occurred on March 1, 2006. In August 2012, Dunkin' Brands became completely independent of the private equity firms. As of 2017, only one Mister Donut store remains in the United States, in Godfrey, Illinois (outside of St. Louis), while there were 10,000 stores worldwide.
=== Legal status === In the United States, it is available only by medical prescription. It is available over the counter in many states in Australia. The product requires labelling by a pharmacist and is only available in packs of two without a medical prescription. However, it can be bought over the counter in the UK and Sweden.
== Structure and basic properties == The N−C−C geometry is linear in nitriles, reflecting the sp hybridization of the triply bonded carbon. The C−N distance is short at 1.16 Å, consistent with a triple bond. Nitriles are polar, as indicated by high dipole moments. As liquids, they have high relative permittivities, often in the 30s.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.